Home › Funds › Cormorant Asset Management, LP › TARS
Cormorant Asset Management, LP position in TARS
TARSUS PHARMACEUTICALS INC · Health Care
Cormorant Asset Management, LP reported holding 100,000 shares of TARS (TARSUS PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$6.3M, representing 0.32% of its reported portfolio and ranking #37 among its reported holdings. Cormorant Asset Management, LP has disclosed TARS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Cormorant Asset Management, LP's TARS position evolved
Cormorant Asset Management, LP first disclosed a stake in TARS in Q3 2023 at 2,621,422 shares (US$46.6M). The position peaked in Q1 2024 at 2,139,102 shares, worth US$77.8M. Across 12 filings, Cormorant Asset Management, LP increased the stake 0 time(s), trimmed it 8 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 100,000 shares valued at US$6.3M — a reduction of -125,000 shares quarter over quarter.. Notable position changes include a 77% trim in Q2 2024 (shares rose 21% over the following quarter), a 25% trim in Q2 2025 (shares rose 47% over the following quarter), a 56% trim in Q2 2026 (shares rose 25% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 2.62M | $46.58M | New |
| Q4 2023 | 2.22M | $44.98M | Reduce |
| Q1 2024 | 2.14M | $77.76M | Reduce |
| Q2 2024 | 500.00K | $13.59M | Reduce |
| Q3 2024 | 500.00K | $16.45M | Hold |
| Q4 2024 | 500.00K | $27.68M | Hold |
| Q1 2025 | 400.00K | $20.55M | Reduce |
| Q2 2025 | 300.00K | $12.15M | Reduce |
| Q3 2025 | 300.00K | $17.83M | Hold |
| Q4 2025 | 250.00K | $20.47M | Reduce |
| Q1 2026 | 225.00K | $15.78M | Reduce |
| Q2 2026 | 100.00K | $6.29M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TARS and 13F data
TARS (TARSUS PHARMACEUTICALS INC) is a Health Care company. 40 other funds we track also report a position in TARS — the largest reported positions include Deep Track Capital, LP (US$230.8M), RTW INVESTMENTS, LP (US$211.3M), Paradigm Biocapital Advisors LP (US$174.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TARS
- Deep Track Capital, LP 3.67M sh · $230.79M · Q2 2026
- RTW INVESTMENTS, LP 3.36M sh · $211.29M · Q2 2026
- Paradigm Biocapital Advisors LP 2.78M sh · $174.70M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.57M sh · $98.71M · Q2 2026
- Vestal Point Capital, LP 1.05M sh · $66.09M · Q2 2026
- Frazier Life Sciences Management, L.P. 728.64K sh · $45.86M · Q2 2026
- Tri Locum Partners LP 328.34K sh · $20.67M · Q2 2026
- MPM BioImpact LLC 322.01K sh · $20.27M · Q2 2026
More on Cormorant Asset Management, LP
FAQ
How long has Cormorant Asset Management, LP held TARS?
Cormorant Asset Management, LP has disclosed TARS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Cormorant Asset Management, LP's current position in TARS?
As of Q2 2026, Cormorant Asset Management, LP holds 100.00K shares of TARS (TARSUS PHARMACEUTICALS INC), valued at $6.29M, representing 0.32% of its reported portfolio and ranking #37.
Has Cormorant Asset Management, LP been buying or selling TARS?
In the latest 13F filing (Q2 2026), Cormorant Asset Management, LP reduced its position in TARS. The position peaked in Q1 2024 at 2.14M shares.
Which other funds hold TARS?
Other major institutional holders of TARS include Deep Track Capital, LP, RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.